Pharmacy Services Department, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE.
Inpatient Pharmacist, The Specialty Hospital, Amman, Jordan.
Am J Clin Oncol. 2020 Jun;43(6):452-455. doi: 10.1097/COC.0000000000000712.
In December 2019, a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of coronavirus disease 2019 (COVID-19). Severe complications have been reported to occur in 33% of patients with COVID-19 and include acute respiratory distress syndrome, acute renal failure, acute respiratory injury, septic shock, and severe pneumonia. Currently, there is no specific treatment or approved vaccine against COVID-19 and many clinical trials are currently investigating potential medications to treat COVID-19. The immunosuppressed status of some cancer patients (whether caused by the disease itself or the treatment) increases their risk of infection compared with the general population. This short review aims to focus on the impact of COVID-19 on a cancer patient and discuss management options and recommendation in addition to highlighting the currently available clinical guidelines and resources.
2019 年 12 月,一种新型冠状病毒——严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引发了 2019 冠状病毒病(COVID-19)疫情。据报道,COVID-19 患者中有 33%出现严重并发症,包括急性呼吸窘迫综合征、急性肾衰竭、急性呼吸损伤、感染性休克和重症肺炎。目前,针对 COVID-19 尚无特定的治疗方法或批准的疫苗,许多临床试验目前正在研究潜在的治疗 COVID-19 的药物。一些癌症患者(无论是由疾病本身还是治疗引起的)的免疫抑制状态使其感染风险高于一般人群。本篇短文旨在重点关注 COVID-19 对癌症患者的影响,并讨论管理方案和建议,同时突出介绍目前可用的临床指南和资源。